MGQLX
Price
$15.67
Change
-$0.38 (-2.37%)
Updated
Dec 18 closing price
RWIBX
Price
$62.66
Change
-$1.77 (-2.75%)
Updated
Dec 18 closing price
Ad is loading...

MGQLX vs RWIBX

Header iconMGQLX vs RWIBX Comparison
Open Charts MGQLX vs RWIBXBanner chart's image
Morgan Stanley Inst Global Stars L
Price$15.67
Change-$0.38 (-2.37%)
VolumeN/A
CapitalizationN/A
American Funds Capital World Gr&Inc R2
Price$62.66
Change-$1.77 (-2.75%)
VolumeN/A
CapitalizationN/A
MGQLX vs RWIBX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MGQLX vs. RWIBX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MGQLX is a Buy and RWIBX is a Buy.

FUNDAMENTALS
Fundamentals
RWIBX has more cash in the bank: 121B vs. MGQLX (61.5M). RWIBX pays higher dividends than MGQLX: RWIBX (1.05) vs MGQLX (0.00). MGQLX was incepted earlier than RWIBX: MGQLX (11 years) vs RWIBX (23 years). MGQLX is a more actively managed with annual turnover of: 34.00 vs. RWIBX (27.00). MGQLX has a lower initial minimum investment than RWIBX: MGQLX (0) vs RWIBX (250). MGQLX annual gain was more profitable for investors over the last year : 19.64 vs. RWIBX (11.34). MGQLX return over 5 years is better than : 47.21 vs. RWIBX (29.64).
MGQLXRWIBXMGQLX / RWIBX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence11 years23 years-
Gain YTD18.2289.781186%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets61.5M121B0%
Annual Yield % from dividends0.001.05-
Returns for 1 year19.6411.34173%
Returns for 3 years15.328.41182%
Returns for 5 years47.2129.64159%
Returns for 10 years85.4044.22193%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LITM0.180.03
+17.46%
Snow Lake Resources Ltd
NUVB2.810.12
+4.46%
Nuvation Bio
ENTG109.362.65
+2.48%
Entegris
ARQ7.01-0.04
-0.57%
Arq
PTCT47.02-1.59
-3.27%
PTC Therapeutics